{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:56:48Z","timestamp":1792799808021,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T00:00:00Z","timestamp":1619740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T00:00:00Z","timestamp":1619740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Sodium\u2013glucose cotransporter 2 inhibitor (SGLT2i) use reduces body weight (BW) in patients with type 2 diabetes mellitus (T2DM). Obesity and T2DM are strong risk factors of new-onset atrial fibrillation (AF). However, whether BW loss following SGLT2i treatment reduces AF risk in patients with T2DM remains unclear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We used a medical database from a multicenter health care provider in Taiwan, which included 10,237 patients with T2DM, from June 1, 2016 to December 31, 2018, whose BW data at baseline and at 12\u00a0weeks of SGLT2i treatment were available. Patients were followed up from the drug index date until the occurrence of new-onset AF, discontinuation of the SGLT2i, or the end of the study period, whichever occurred first.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The patients\u2019 baseline body mass index (BMI) was 28.08<jats:inline-formula><jats:alternatives><jats:tex-math>$$\\pm$$<\/jats:tex-math><mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\"><mml:mo>\u00b1<\/mml:mo><\/mml:math><\/jats:alternatives><\/jats:inline-formula>4.88\u00a0kg\/m<jats:sup>2<\/jats:sup>. SGLT2i treatment was associated with a BW loss of 1.35<jats:inline-formula><jats:alternatives><jats:tex-math>$$\\pm$$<\/jats:tex-math><mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\"><mml:mo>\u00b1<\/mml:mo><\/mml:math><\/jats:alternatives><\/jats:inline-formula>3.28\u00a0kg (1.78%<jats:inline-formula><jats:alternatives><jats:tex-math>$$\\pm$$<\/jats:tex-math><mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\"><mml:mo>\u00b1<\/mml:mo><\/mml:math><\/jats:alternatives><\/jats:inline-formula>4.47%). There were 37.4%, 47.0%, and 15.6% of patients experienced no-BW loss (n\u2009=\u20093832), BW loss 0.0\u20134.9% (n\u2009=\u20094814), and<jats:inline-formula><jats:alternatives><jats:tex-math>$$\\ge$$<\/jats:tex-math><mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\"><mml:mo>\u2265<\/mml:mo><\/mml:math><\/jats:alternatives><\/jats:inline-formula>5.0% (n\u2009=\u20091591) following SGLT2i treatment, respectively. Compared with patients with baseline BMI\u2009&lt;\u200923\u00a0kg\/m<jats:sup>2<\/jats:sup>, AF risk significantly increased in patients with baseline BMI<jats:inline-formula><jats:alternatives><jats:tex-math>$$\\ge$$<\/jats:tex-math><mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\"><mml:mo>\u2265<\/mml:mo><\/mml:math><\/jats:alternatives><\/jats:inline-formula>27.5\u00a0kg\/m<jats:sup>2<\/jats:sup>(<jats:italic>P<\/jats:italic>for trend\u2009=\u20090.015). Compared with those without BW loss after SGLT2i treatment, AF risk significantly decreased with a BW loss of<jats:inline-formula><jats:alternatives><jats:tex-math>$$\\ge$$<\/jats:tex-math><mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\"><mml:mo>\u2265<\/mml:mo><\/mml:math><\/jats:alternatives><\/jats:inline-formula>5.0% (adjusted hazard ratios [95% confidence intervals]: 0.39[0.22\u20130.68]). Use of diuretics, old age, high-dose SGLT2i, higher estimated glomerular filtration rate, and baseline BMI were independent factors associated with a BW loss of<jats:inline-formula><jats:alternatives><jats:tex-math>$$\\ge$$<\/jats:tex-math><mml:math xmlns:mml=\"http:\/\/www.w3.org\/1998\/Math\/MathML\"><mml:mo>\u2265<\/mml:mo><\/mml:math><\/jats:alternatives><\/jats:inline-formula>5.0% following SGLT2i initiation. By contrast, neither baseline BMI nor BW loss after SGLT2i treatment predicted major cardiovascular adverse events or heart failure hospitalization risk (<jats:italic>P<\/jats:italic>for trend\u2009&gt;\u20090.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>BW loss of\u2009\u2265\u20095.0% following SGLT2i treatment was associated with a lower risk of new-onset AF in patients with T2DM in real-world practice.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12933-021-01285-8","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T09:03:22Z","timestamp":1620032602000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["The impact of weight loss related to risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium\u2013glucose cotransporter 2 inhibitor"],"prefix":"10.1186","volume":"20","author":[{"given":"Yi-Hsin","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tze-Fan","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Wei","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Ying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pao-Hsien","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,30]]},"reference":[{"issue":"2","key":"1285_CR1","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"CT January","year":"2019","unstructured":"January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, Ellinor PT, Ezekowitz MD, Field ME, Furie KL, et al. 2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American heart association task force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons. Circulation. 2019;140(2):e125\u201351.","journal-title":"Circulation"},{"issue":"2","key":"1285_CR2","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/dom.13512","volume":"21","author":"DSH Bell","year":"2019","unstructured":"Bell DSH, Goncalves E. Atrial fibrillation and type 2 diabetes: Prevalence, etiology, pathophysiology and effect of anti-diabetic therapies. Diabetes Obes Metab. 2019;21(2):210\u20137.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"1285_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.amjcard.2011.03.004","volume":"108","author":"RR Huxley","year":"2011","unstructured":"Huxley RR, Filion KB, Konety S, Alonso A. Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol. 2011;108(1):56\u201362.","journal-title":"Am J Cardiol"},{"issue":"8","key":"1285_CR4","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.jacc.2019.07.020","volume":"74","author":"A Wang","year":"2019","unstructured":"Wang A, Green JB, Halperin JL, Piccini JP Sr. Atrial fibrillation and diabetes mellitus: JACC review topic of the week. J Am Coll Cardiol. 2019;74(8):1107\u201315.","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"1285_CR5","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.jacc.2018.06.040","volume":"72","author":"TA Zelniker","year":"2018","unstructured":"Zelniker TA, Braunwald E. Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC State-of-the-Art review. J Am Coll Cardiol. 2018;72(15):1845\u201355.","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"1285_CR6","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"7","key":"1285_CR7","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"4","key":"1285_CR8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, et al. Dapagliflozin and cardiovascular outcomes in Type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"15","key":"1285_CR9","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","volume":"141","author":"TA Zelniker","year":"2020","unstructured":"Zelniker TA, Bonaca MP, Furtado RHM, Mosenzon O, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, et al. Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial. Circulation. 2020;141(15):1227\u201334.","journal-title":"Circulation"},{"issue":"1","key":"1285_CR10","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12933-020-01162-w","volume":"19","author":"AW Ling","year":"2020","unstructured":"Ling AW, Chan CC, Chen SW, Kao YW, Huang CY, Chan YH, Chu PH. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors. Cardiovasc Diabetol. 2020;19(1):188.","journal-title":"Cardiovasc Diabetol"},{"issue":"16","key":"1285_CR11","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1016\/j.jacc.2017.09.002","volume":"70","author":"CJ Lavie","year":"2017","unstructured":"Lavie CJ, Pandey A, Lau DH, Alpert MA, Sanders P. Obesity and atrial fibrillation prevalence, pathogenesis, and prognosis: effects of weight loss and exercise. J Am Coll Cardiol. 2017;70(16):2022\u201335.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1285_CR12","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12933-019-0964-4","volume":"18","author":"Q Shao","year":"2019","unstructured":"Shao Q, Meng L, Lee S, Tse G, Gong M, Zhang Z, Zhao J, Zhao Y, Li G, Liu T. Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet\/streptozotocin-induced diabetic rats. Cardiovasc Diabetol. 2019;18(1):165.","journal-title":"Cardiovasc Diabetol"},{"issue":"20","key":"1285_CR13","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1016\/j.jacc.2015.03.002","volume":"65","author":"RK Pathak","year":"2015","unstructured":"Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX, Twomey D, Elliott AD, Kalman JM, Abhayaratna WP, et al. Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY). J Am Coll Cardiol. 2015;65(20):2159\u201369.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1285_CR14","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/pds.4713","volume":"28","author":"SC Shao","year":"2019","unstructured":"Shao SC, Chan YY, Kao Yang YH, Lin SJ, Hung MJ, Chien RN, Lai CC, Lai EC. The chang gung research database-a multi-institutional electronic medical records database for real-world epidemiological studies in Taiwan. Pharmacoepidemiol Drug Saf. 2019;28(5):593\u2013600.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"1285_CR15","doi-asserted-by":"publisher","first-page":"154","DOI":"10.4103\/0970-0218.173492","volume":"41","author":"S Girdhar","year":"2016","unstructured":"Girdhar S, Sharma S, Chaudhary A, Bansal P, Satija M. An epidemiological study of overweight and obesity among women in an urban area of North India. Indian J Community Med. 2016;41(2):154\u20137.","journal-title":"Indian J Community Med"},{"issue":"2","key":"1285_CR16","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1249\/MSS.0b013e3181949333","volume":"41","author":"JE Donnelly","year":"2009","unstructured":"Donnelly JE, Blair SN, Jakicic JM, Manore MM, Rankin JW, Smith BK. American College of Sports M: American College of Sports Medicine Position Stand. Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults. Med Sci Sports Exerc. 2009;41(2):459\u201371.","journal-title":"Med Sci Sports Exerc"},{"issue":"4","key":"1285_CR17","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/oby.21404","volume":"24","author":"DL Swift","year":"2016","unstructured":"Swift DL, Johannsen NM, Lavie CJ, Earnest CP, Blair SN, Church TS. Effects of clinically significant weight loss with exercise training on insulin resistance and cardiometabolic adaptations. Obesity. 2016;24(4):812\u20139.","journal-title":"Obesity"},{"issue":"5","key":"1285_CR18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jjcc.2015.04.002","volume":"66","author":"CA Goudis","year":"2015","unstructured":"Goudis CA, Korantzopoulos P, Ntalas IV, Kallergis EM, Ketikoglou DG. Obesity and atrial fibrillation: a comprehensive review of the pathophysiological mechanisms and links. J Cardiol. 2015;66(5):361\u20139.","journal-title":"J Cardiol"},{"key":"1285_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12933-014-0170-3","volume":"14","author":"I Grundvold","year":"2015","unstructured":"Grundvold I, Bodegard J, Nilsson PM, Svennblad B, Johansson G, Ostgren CJ, Sundstrom J. Body weight and risk of atrial fibrillation in 7,169 patients with newly diagnosed type 2 diabetes; an observational study. Cardiovasc Diabetol. 2015;14:5.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1285_CR20","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12933-019-0932-z","volume":"18","author":"YG Kim","year":"2019","unstructured":"Kim YG, Han KD, Choi JI, Boo KY, Kim DY, Oh SK, Lee KN, Shim J, Kim JS, Kim YH. The impact of body weight and diabetes on new-onset atrial fibrillation: a nationwide population based study. Cardiovasc Diabetol. 2019;18(1):128.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1285_CR21","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12933-017-0604-9","volume":"16","author":"BS Karam","year":"2017","unstructured":"Karam BS, Chavez-Moreno A, Koh W, Akar JG, Akar FG. Oxidative stress and inflammation as central mediators of atrial fibrillation in obesity and diabetes. Cardiovasc Diabetol. 2017;16(1):120.","journal-title":"Cardiovasc Diabetol"},{"issue":"20","key":"1285_CR22","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1161\/CIRCULATIONAHA.118.035202","volume":"138","author":"C Yao","year":"2018","unstructured":"Yao C, Veleva T, Scott L Jr, Cao S, Li L, Chen G, Jeyabal P, Pan X, Alsina KM, Abu-Taha ID, et al. Enhanced cardiomyocyte NLRP3 inflammasome signaling promotes atrial fibrillation. Circulation. 2018;138(20):2227\u201342.","journal-title":"Circulation"},{"issue":"13","key":"1285_CR23","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.jacep.2020.08.008","volume":"6","author":"MJ Singleton","year":"2020","unstructured":"Singleton MJ, German CA, Soliman EZ, Whalen SP, Bhave PD, Bertoni AG, Yeboah J. Body mass index, sex, and incident atrial fibrillation in diabetes: the ACCORD trial. JACC Clin Electrophysiol. 2020;6(13):1713\u201320.","journal-title":"JACC Clin Electrophysiol"},{"issue":"2","key":"1285_CR24","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/1479164114561992","volume":"12","author":"LA Gallo","year":"2015","unstructured":"Gallo LA, Wright EM, Vallon V. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res. 2015;12(2):78\u201389.","journal-title":"Diab Vasc Dis Res"},{"issue":"10","key":"1285_CR25","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.2337\/dc13-0387","volume":"36","author":"RA DeFronzo","year":"2013","unstructured":"DeFronzo RA, Hompesch M, Kasichayanula S, Liu X, Hong Y, Pfister M, Morrow LA, Leslie BR, Boulton DW, Ching A, et al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care. 2013;36(10):3169\u201376.","journal-title":"Diabetes Care"},{"key":"1285_CR26","doi-asserted-by":"crossref","unstructured":"Trum M, Riechel J, Lebek S, Pabel S, Sossalla ST, Hirt S, Arzt M, Maier LS, Wagner S. Empagliflozin inhibits Na(+) \/H(+) exchanger activity in human atrial cardiomyocytes. ESC Heart Fail 2020.","DOI":"10.1002\/ehf2.13024"},{"issue":"8","key":"1285_CR27","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1089\/ars.2013.5542","volume":"20","author":"AC Pinho-Gomes","year":"2014","unstructured":"Pinho-Gomes AC, Reilly S, Brandes RP, Casadei B. Targeting inflammation and oxidative stress in atrial fibrillation: role of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibition with statins. Antioxid Redox Signal. 2014;20(8):1268\u201385.","journal-title":"Antioxid Redox Signal"},{"issue":"1","key":"1285_CR28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12933-019-0984-0","volume":"19","author":"SR Yurista","year":"2020","unstructured":"Yurista SR, Sillje HHW, Rienstra M, de Boer RA, Westenbrink BD. Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes? Cardiovasc Diabetol. 2020;19(1):5.","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"1285_CR29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/cvr\/cvu045","volume":"102","author":"SN Hatem","year":"2014","unstructured":"Hatem SN, Sanders P. Epicardial adipose tissue and atrial fibrillation. Cardiovasc Res. 2014;102(2):205\u201313.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"1285_CR30","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12933-017-0658-8","volume":"17","author":"T Sato","year":"2018","unstructured":"Sato T, Aizawa Y, Yuasa S, Kishi S, Fuse K, Fujita S, Ikeda Y, Kitazawa H, Takahashi M, Sato M, et al. The effect of dapagliflozin treatment on epicardial adipose tissue volume. Cardiovasc Diabetol. 2018;17(1):6.","journal-title":"Cardiovasc Diabetol"},{"key":"1285_CR31","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","volume":"141","author":"TA Zelniker","year":"2020","unstructured":"Zelniker TA, Bonaca MP, Furtado R, Mosenzon O, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, et al. Effect of Dapagliflozin on Atrial Fibrillation in patients with Type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial. Circulation. 2020;141:1227\u201334.","journal-title":"Circulation"},{"issue":"1","key":"1285_CR32","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/dom.14211","volume":"23","author":"V Okunrintemi","year":"2021","unstructured":"Okunrintemi V, Mishriky BM, Powell JR, Cummings DM. Sodium-glucose co-transporter-2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials. Diabetes Obes Metab. 2021;23(1):276\u201380.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"1285_CR33","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.ahj.2015.07.026","volume":"170","author":"A Alonso","year":"2015","unstructured":"Alonso A, Bahnson JL, Gaussoin SA, Bertoni AG, Johnson KC, Lewis CE, Vetter M, Mantzoros CS, Jeffery RW, Soliman EZ, et al. Effect of an intensive lifestyle intervention on atrial fibrillation risk in individuals with type 2 diabetes: the Look AHEAD randomized trial. Am Heart J. 2015;170(4):770-777 e775.","journal-title":"Am Heart J"},{"issue":"9","key":"1285_CR34","doi-asserted-by":"publisher","first-page":"e008414","DOI":"10.1161\/JAHA.117.008414","volume":"7","author":"J Ball","year":"2018","unstructured":"Ball J, Lochen ML, Wilsgaard T, Schirmer H, Hopstock LA, Morseth B, Mathiesen EB, Njolstad I, Tiwari S, Sharashova E. Sex Differences in the Impact of body mass index on the risk of future Atrial Fibrillation: insights from the longitudinal population-based tromso study. J Am Heart Assoc. 2018;7(9):e008414.","journal-title":"J Am Heart Assoc"},{"key":"1285_CR35","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ahj.2015.11.016","volume":"173","author":"A Berkovitch","year":"2016","unstructured":"Berkovitch A, Kivity S, Klempfner R, Segev S, Milwidsky A, Erez A, Sabbag A, Goldenberg I, Sidi Y, Maor E. Body mass index and the risk of new-onset atrial fibrillation in middle-aged adults. Am Heart J. 2016;173:41\u20138.","journal-title":"Am Heart J"},{"issue":"23","key":"1285_CR36","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1016\/j.jacc.2016.09.940","volume":"68","author":"S Jamaly","year":"2016","unstructured":"Jamaly S, Carlsson L, Peltonen M, Jacobson P, Sjostrom L, Karason K. Bariatric surgery and the risk of new-onset Atrial Fibrillation in swedish obese subjects. J Am Coll Cardiol. 2016;68(23):2497\u2013504.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1285_CR37","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1161\/CIRCEP.113.001244","volume":"7","author":"RR Huxley","year":"2014","unstructured":"Huxley RR, Misialek JR, Agarwal SK, Loehr LR, Soliman EZ, Chen LY, Alonso A. Physical activity, obesity, weight change, and risk of atrial fibrillation: the atherosclerosis risk in communities study. Circ Arrhythm Electrophysiol. 2014;7(4):620\u20135.","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"23","key":"1285_CR38","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1136\/heartjnl-2019-314931","volume":"105","author":"NR Jones","year":"2019","unstructured":"Jones NR, Taylor KS, Taylor CJ, Aveyard P. Weight change and the risk of incident atrial fibrillation: a systematic review and meta-analysis. Heart. 2019;105(23):1799\u2013805.","journal-title":"Heart"},{"issue":"3","key":"1285_CR39","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40265-019-1057-0","volume":"79","author":"MJ Pereira","year":"2019","unstructured":"Pereira MJ, Eriksson JW. Emerging role of SGLT-2 inhibitors for the treatment of obesity. Drugs. 2019;79(3):219\u201330.","journal-title":"Drugs"},{"issue":"23","key":"1285_CR40","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1056\/NEJMoa066224","volume":"355","author":"SE Kahn","year":"2006","unstructured":"Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O\u2019Neill MC, Zinman B, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427\u201343.","journal-title":"N Engl J Med"},{"issue":"5","key":"1285_CR41","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/j.1463-1326.2011.01552.x","volume":"14","author":"CL Morgan","year":"2012","unstructured":"Morgan CL, Jenkins-Jones S, Evans M, Barnett AH, Poole CD, Currie CJ. Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs. Diabetes Obes Metab. 2012;14(5):424\u201332.","journal-title":"Diabetes Obes Metab"},{"issue":"10193","key":"1285_CR42","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Ryden L, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121\u201330.","journal-title":"Lancet"},{"issue":"19","key":"1285_CR43","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"issue":"4","key":"1285_CR44","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"1","key":"1285_CR45","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.diabres.2015.07.015","volume":"110","author":"F Sun","year":"2015","unstructured":"Sun F, Wu S, Guo S, Yu K, Yang Z, Li L, Zhang Y, Quan X, Ji L, Zhan S. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Res Clin Pract. 2015;110(1):26\u201337.","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"1285_CR46","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/bcp.12843","volume":"81","author":"MM Smits","year":"2016","unstructured":"Smits MM, Muskiet MH, Tonneijck L, Hoekstra T, Kramer MH, Diamant M, van Raalte DH. Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males. Br J Clin Pharmacol. 2016;81(4):613\u201320.","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"1285_CR47","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S2213-8587(15)00233-8","volume":"3","author":"M Fisher","year":"2015","unstructured":"Fisher M, Petrie MC, Ambery PD, Donaldson J, Ye J, McMurray JJ. Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis. Lancet Diabetes Endocrinol. 2015;3(9):697\u2013703.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"1285_CR48","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s40618-017-0698-7","volume":"40","author":"M Monami","year":"2017","unstructured":"Monami M, Nreu B, Scatena A, Giannini S, Andreozzi F, Sesti G, Mannucci E. Glucagon-like peptide-1 receptor agonists and atrial fibrillation: a systematic review and meta-analysis of randomised controlled trials. J Endocrinol Invest. 2017;40(11):1251\u20138.","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"1285_CR49","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/obr.12841","volume":"20","author":"E Brown","year":"2019","unstructured":"Brown E, Wilding JPH, Barber TM, Alam U, Cuthbertson DJ. Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: mechanistic possibilities. Obes Rev. 2019;20(6):816\u201328.","journal-title":"Obes Rev"},{"key":"1285_CR50","first-page":"525","volume":"7","author":"NS Ahmad","year":"2013","unstructured":"Ahmad NS, Ramli A, Islahudin F, Paraidathathu T. Medication adherence in patients with type 2 diabetes mellitus treated at primary health clinics in Malaysia. Patient Prefer Adherence. 2013;7:525\u201330.","journal-title":"Patient Prefer Adherence"},{"issue":"28","key":"1285_CR51","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1093\/eurheartj\/ehaa293","volume":"41","author":"W Doehner","year":"2020","unstructured":"Doehner W, Gerstein HC, Ried J, Jung H, Asbrand C, Hess S, Anker SD. Obesity and weight loss are inversely related to mortality and cardiovascular outcome in prediabetes and type 2 diabetes: data from the ORIGIN trial. Eur Heart J. 2020;41(28):2668\u201377.","journal-title":"Eur Heart J"},{"issue":"2","key":"1285_CR52","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJMoa1212914","volume":"369","author":"ARG Look","year":"2013","unstructured":"Look ARG, Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, Crow RS, Curtis JM, Egan CM, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145\u201354.","journal-title":"N Engl J Med"},{"issue":"5","key":"1285_CR53","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/ehf2.12505","volume":"6","author":"NSR Lan","year":"2019","unstructured":"Lan NSR, Fegan PG, Yeap BB, Dwivedi G. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions. ESC Heart Fail. 2019;6(5):927\u201335.","journal-title":"ESC Heart Fail"},{"issue":"13","key":"1285_CR54","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/j.jacc.2018.08.1037","volume":"72","author":"CJ Lavie","year":"2018","unstructured":"Lavie CJ, Laddu D, Arena R, Ortega FB, Alpert MA, Kushner RF. Healthy weight and obesity prevention: JACC health promotion series. J Am Coll Cardiol. 2018;72(13):1506\u201331.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1285_CR55","doi-asserted-by":"publisher","first-page":"e000742","DOI":"10.1136\/bmjdrc-2019-000742","volume":"7","author":"SC Shao","year":"2019","unstructured":"Shao SC, Lin YH, Chang KC, Chan YY, Hung MJ, Kao Yang YH, Lai EC. Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients? BMJ Open Diabetes Res Care. 2019;7(1):e000742.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"20","key":"1285_CR56","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1001\/jama.2009.726","volume":"301","author":"JC Chan","year":"2009","unstructured":"Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, Hu FB. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009;301(20):2129\u201340.","journal-title":"JAMA"},{"issue":"5","key":"1285_CR57","doi-asserted-by":"publisher","first-page":"e19835","DOI":"10.1371\/journal.pone.0019835","volume":"6","author":"D Wang","year":"2011","unstructured":"Wang D, Li Y, Lee SG, Wang L, Fan J, Zhang G, Wu J, Ji Y, Li S. Ethnic differences in body composition and obesity related risk factors: study in Chinese and white males living in China. PLoS ONE. 2011;6(5):e19835.","journal-title":"PLoS ONE"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-021-01285-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-021-01285-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-021-01285-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T05:13:06Z","timestamp":1698988386000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-021-01285-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,30]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["1285"],"URL":"https:\/\/doi.org\/10.1186\/s12933-021-01285-8","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,30]]},"assertion":[{"value":"10 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol complies with the Declaration of Helsinki and was approved by the Institutional Review Board of the Chang Gung Medical Foundation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"93"}}